Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Generic Version Of Vagifem In U.S. Impacts Novo Nordisk Biopharma Sales

By Novo Nordisk A/S | February 1, 2018

Reported sales were broadly unchanged at $16.9 billion (2 percent growth in local currencies).

Sales within biopharmaceuticals declined by 18 percent to $2.9 billion (16 percent in local currencies), reflecting the impact in the U.S. from the introduction of a generic version of the hormone replacement therapy product Vagifem and a rebate adjustment for growth hormone in Q1 2016. Sales within hemophilia were broadly unchanged (2 percent growth in local currencies).

Sales within International Operations increased by 2 percent in Danish kroner (5 percent in local currencies) driven by sales growth in all business regions measured in local currencies. Sales within North America Operations decreased by 2 percent in Danish kroner and were unchanged in local currencies, reflecting the non-recurring effects in biopharmaceuticals impacting growth negatively by 4 percentage points.

Operating profit increased by 1 percent reported in Danish kroner and by 5 percent in local currencies to $7.4 billion. Net profit increased by 1 percent to $5.8 billion. Diluted earnings per share increased by 3 percent to $2.33.

In December, Novo Nordisk received the U.S. Food and Drug Administration (FDA) approval of Ozempic (semaglutide) for treatment of people with type 2 diabetes and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) recommending marketing authorization for Ozempic. Ozempic will to be launched in the U.S. next week.

Chairman of the Board of Directors Göran Ando has decided not to seek re-election at the Annual General Meeting in March 2018. The board proposes current member Helge Lund to be elected as chairman.

As of February 15, 2018, Karsten Munk Knudsen, currently senior vice president of Corporate Finance, will succeed Jesper Brandgaard as chief financial officer. Jesper Brandgaard will continue as executive vice president responsible for Biopharm and Legal Affairs.      

For 2018, sales growth is expected to be 2-5 percent measured in local currencies and operating profit growth is expected to be 1-5 percent. Sales growth reported in Danish kroner is expected to be 7 percentage points lower than in local currencies, reflecting the significant depreciation of the U.S. dollar and related currencies versus the Danish krone. Likewise, reported operating profit growth is expected to be 10 percentage points lower.

At the Annual General Meeting on March 22, 2018, the board will propose a final dividend of $0.78 for 2017 per share of DKK 0.20. The expected total dividend for 2017 of $1.26 per share, of which $0.48 per share was paid as interim dividend in August 2017, corresponds to an increase of 3 percent compared to 2016. The board furthermore intends to initiate a new 12-month share repurchase program of up to $2.3 billion.

“The approval of Ozempic in the U.S. was the culmination of a year in which we achieved important product approvals and label updates,” Lars Fruergaard Jørgensen, president and CEO, said. “In 2018, we will focus on the global launch of Ozempic and pursue the full value potential of our strong product portfolio in what continues to be a competitive environment.”

(Source: Novo Nordisk A/S)


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE